The innate immune response status correlates with a divergent clinical course in congenital Chagas disease of twins born in a non-endemic country

Acta Tropica

Volumn 140, Issue , 2014, Pages 84-90

  Fernández Villegas, Ana ^a   Thomas, M Carmen ^a   Carrilero, Bartolomé ^b   Téllez, Cinta ^b   Marañón, Concepción ^a   Murcia, Laura ^b   Moralo, Sara ^b   Alonso, Carlos ^c   Segovia, Manuel ^b,d   López, Manuel Carlos ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c CSIC   (Spain)

^d HVA   (Spain)

Author keywords

Chagas disease; Congenital transmission; Innate immune response; PCR; Serological biomarker; Trypanosoma cruzi

Indexed keywords

ALPHA INTERFERON; BENZNIDAZOLE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; HEAT SHOCK PROTEIN 70; MEMBRANE PROTEIN; PROTEIN KMP11; PROTEIN PFR2; PROTEIN TGP63; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; CYTOKINE; NITROIMIDAZOLE DERIVATIVE;

BIOMARKER; CHAGAS DISEASE; DISEASE TREATMENT; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTIVITY; INNATE BEHAVIOR; POLYMERASE CHAIN REACTION; DISEASE INCIDENCE; DISEASE PREVALENCE; IMMUNITY;

ARTICLE; CHAGAS DISEASE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN CELL; INFANT; INNATE IMMUNITY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEROLOGY; SPAIN; SYMPTOMATOLOGY; TRYPANOSOMA CRUZI; TWINS; ADULT; CASE REPORT; CORRELATION ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; FEMALE; HEART DISEASE; IMMUNE RESPONSE; IMMUNOREACTIVITY; PARASITE IDENTIFICATION; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SPLENOMEGALY; YOUNG ADULT; CONGENITAL; DIZYGOTIC TWINS; IMMUNOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; SECRETION (PROCESS); TRANSMISSION; VERTICAL TRANSMISSION;

TRYPANOSOMA CRUZI;

ADULT; CHAGAS DISEASE; CYTOKINES; DISEASES IN TWINS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NITROIMIDAZOLES; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; SPAIN; TRYPANOCIDAL AGENTS; TWINS, DIZYGOTIC;

EID: 84906737324     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2014.08.006     Document Type: Article

References (31)

1. Bern C., Martin D.L., Gilman R.H. Acute and congenital Chagas disease. Adv. Parasitol. 2011, 75:19-47.
2. Blanco S.B., Segura E.L., Cura E.N., Chuit R., Tulian L., Flores I., Garbarino G., Villalonga J.F., Gurtler R.E. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop. Med. Int. Health 2000, 5:293-301.
3. Burgos J.M., Altcheh J., Bisio M., Duffy T., Valadares H.M., Seidenstein M.E., Piccinali R., Freitas J.M., Levin M.J., Macchi L., Macedo A.M., Freilij H., Schijman A.G. Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas disease. Int. J. Parasitol. 2007, 37:1319-1327.
4. Brutus L., Castillo H., Bernal C., Salas N.A., Schneider D., Santalla J.A., Chippaux J.P. Detectable Trypanosoma cruzi parasitemia during pregnancy and delivery as a risk factor for congenital Chagas disease. Am. J. Trop. Med. Hyg. 2010, 83:1044-1047.
5. CDC Congenital transmission of Chagas disease-Virginia. Morb. Mortal. Wkly. Rep. 2012, 61:477-479.
6. Caldas I.S., Talvani A., Caldas S., Carneiro C.M., de Lana M., da Matta Guedes P.M., Bahia M.T. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol. Res. 2008, 103:413-421.
7. Carlier Y., Truyens C. Maternal-fetal transmission of T. cruzi. American Trypanosomiasis: Chagas Disease-One Hundred Years of Research 2010, 539-581. Elsevier, London, UK/Burlington, MA. J. Telleria, M. Tibayrenc (Eds.).
8. Carlier Y., Torrico F., Sosa-Estani S., Russomando G., Luquetti A., Freilij H., Albajar-Vinas P. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl. Trop. Dis. 2011, 10:e1250.
9. Corrales R.M., Mora M.C., Negrette O.S., Diosque P., Lacunza D., Virreira M., Breniere S.F., Basombrio M.A. Congenital Chagas disease involves Trypanosoma cruzi sub-lineage IId in the northwestern province of Salta, Argentina. Infect. Genet. Evol. 2009, 9:278-282.
10. Dauby N., Alonso-Vega C., Suarez E., Flores A., Hermann E., Córdova M., Tellez T., Torrico F., Truyens C., Carlier Y. Maternal infection with Trypanosoma cruzi and congenital Chagas disease induce a trend to a type 1 polarization of infant immune responses to vaccines. PLoS Negl. Trop. Dis. 2009, 3(12):e571.
11. Fernandez-Villegas A., Pinazo M.J., Maranon C., Thomas M.C., Posada E., Carrilero B., Segovia M., Gascon J., Lopez M.C. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers. BMC Infect. Dis. 2011, 11:206.
12. Honda K., Yanai H., Takaoka A., Taniguchi T. Regulation of the type I IFN induction: a current view. Int. Immunol. 2005, 17:1367-1378.
13. Howard E.J., Xiong X., Carlier Y., Sosa-Estani S., Buekens P. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 2014, 121(1):22-33.
14. Jackson Y., Myers C., Diana A., Marti H.P., Wolff H., Chappuis F., Loutan L., Gervaix A. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg. Infect. Dis. 2009, 15:601-603.
15. Kayama H., Takeda K. The innate immune response to Trypanosoma cruzi infection. Microbes Infect. 2010, 12(7):511-517.
16. Macedo A., Sagetto M. Implications of Trypanosoma cruzi intraespecific diversity in ten pathogenesis of Chagas disease. American Trypanosomiasis: Chagas Disease-One Hundred Years of Research 2010, 489-522. Elsevier, London, UK/Burlington, MA, USA. J. Telleria, M. Tibayrenc (Eds.).
17. Marañón C., Planelles L., Alonso C., Lopez M.C. HSP70 from Trypanosoma cruzi is endowed with specific cell proliferation potential leading to apoptosis. Int. Immunol. 2000, 12:1685-1693.
18. Morell M., Thomas M.C., Caballero T., Alonso C., Lopez M.C. The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine 2006, 24:7046-7055.
19. Muñoz J., Coll O., Juncosa T., Verges M., del Pino M., Fumado V., Bosch J., Posada E.J., Hernandez S., Fisa R., Boguña J.M., Gállego M., Sanz S., Portús M., Gascón J. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin. Infect. Dis. 2009, 48:1736-1740.
20. Muñoz J., Gomez Prat J., Gallego M., Gimeno F., Trevino B., Lopez-Chejade P., Ribera O., Molina L., Sanz S., Pinazo M.J., Riera C., Posada E.J., Sanz G., Portus M., Gascon J. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009, 111:51-55.
21. Muñoz-Calderón A., Díaz-Bello Z., Valladares B., Noya O., López M.C., Alarcón de Noya B., Thomas M.C. Oral transmission of Chagas disease: typing of Trypanosoma cruzi from five outbreaks occurred in Venezuela shows multiclonal and common infections in patients, vectors and reservoirs. Infec. Genet. Evol. 2013, 17:113-122.
22. Murcia L., Carrilero B., Munoz M.J., Iborra M.A., Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. J. Antimicrob. Chemother. 2010, 65:1759-1764.
23. Murcia L., Carrilero B., Munoz-Davila M.J., Thomas M.C., Lopez M.C., Segovia M. Risk factors and primary prevention of congenital Chagas disease in a nonendemic country. Clin. Infect. Dis. 2013, 56:496-502.
24. Ponce N.E., Cano R.C., Carrera-Silva E.A., Lima A.P., Gea S., Aoki M.P. Toll-like receptor-2 and interleukin-6 mediate cardiomyocyte protection from apoptosis during Trypanosoma cruzi murine infection. Med. Microbiol. Immunol. 2012, 201:145-155.
25. Rodrigues M.M., Oliveira A.C., Bellio M. The immune response to Trypanosoma cruzi: role of roll-like receptors and perspectives for vaccine development. J. Parasitol. Res. 2012, 2012:1-12. ID 507874.
26. Thomas M.C., Garcia-Perez J.L., Alonso C., Lopez M.C. Molecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeleton-associated protein regulated at the translational level. DNA Cell Biol. 2000, 19:47-57.
27. Truyens C., Hermann E., Alonso-Vega C., Rodriguez P., Vekemans J., Torrico F., Carlier Y. Immune responses of non-infected neonates of mothers infected with Trypanosoma cruzi. Rev. Soc. Bras. Med. Trop. 2005, 38(2):96-100.
28. Vekemans J., Truyens C., Torrico F., Solano M., Torrico M.C., Rodriguez P., Alonso-Vega C., Carlier Y. Maternal Trypanosoma cruzi infection upregulates capacity of uninfected neonate cells T produce pro- and anti-inflammatory cytokines. Infect. Immun. 2000, 68:5430-5434.
29. Viotti R., Alarcón de Noya B., Araujo-Jorge T., Grijalva M., Guhl F., López M.C., Ramsey J., Ribeiro I., Schijman A., Sosa-Estani S., Torrico F., Gascon J. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob. Agents Chemother. 2014, 58(2):635-639.
30. Control of Chagas disease. World Health Organ. Tech. Rep. Ser. 2002, 905:1-109. World Health Organization (WHO), back cover.
31. World Health Organization (WHO) Chagas Disease (American trypanosomiasis) 2012, 87:519-522. World Health Organization (WHO).